{"id":"nct:NCT01931566","kind":"trial","title":"Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset","authors":["Takeda"],"author_count":1,"year":2013,"published":"2013-08-29","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT01931566","source_url":"https://clinicaltrials.gov/study/NCT01931566","archive_url":"https://space-kitty.com/papers/nct:NCT01931566","updated":"2019-09-16","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone compared with placebo to delay the onset of MCI-AD in cognitively-normal participants who are at high-risk for developing MCI within 5 years.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Mild Cognitive Impairment Due to Alzheimer's Disease"],"details":{"acronym":"TOMMORROW","status":"TERMINATED","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":3494,"sponsor":"Takeda","conditions":["Mild Cognitive Impairment Due to Alzheimer's Disease"],"interventions":["DRUG: Pioglitazone","DRUG: Pioglitazone placebo"],"start_date":"2013-08-01","start_date_type":"ACTUAL","primary_completion_date":"2018-07-24","has_results":true,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}